NanoViricides, Inc. (OTC BB: NNVC.OB)

Turning Pennies into dollars: NanoViricides, Inc. (OTC BB: NNVC.OB)

Are you a public company looking for exposure?

Contact RealPennies.com - 212-662-2147



For more info: http://www.realpennies.com/otc/nnvc

Monday April 6, 2009, 7:00 am EDT

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), is providing a summary of its achievements over the past 12 months.

Most significantly, the Company reported in June, 2008, that animals treated with its anti-HIV lead drug candidate exhibited survival time superior to that of animals treated with the standard three drug oral cocktail called HAART. These studies employed the well established SCID-Hu Thy/Liv mouse model and were conducted by KARD Scientific, Inc. The Company plans to perform additional studies to obtain further detailed information regarding the effect of the nanoviricide drug candidates on HIV in vivo.

NanoViricides, Inc. has reported in May, 2008, that its anti-EKC (epidemic keratoconjunctivitis) drug candidate exhibited excellent clinical improvement in an ophthalmic adenovirus infection animal model of this disease. These studies were conducted by scientists at the Feinstein Institute of Medical Research (FIMR), part of the North Shore-LIJ Health System. These studies were presented by the FIMR scientists at the 42nd annual meeting of the Ocular Microbiology and Immunology Group (OMIG) in Atlanta, Georgia, in November 2008. In addition, evaluation of our ophthalmic anti-herpes nanoviricide drug candidates will begin shortly at a renowned School of Veterinary Medicine in the US.

The Company further reports satisfactory progress in its anti-Rabies program. These studies are continuing at the US Centers for Diseases Control and Prevention (CDC).

The Company is presently in discussions with an independent research facility to perform anti-H5N1 animal studies with the Company’s drug candidates that were highly successful against H5N1 Clade 1 and Clade 2 in cell cultures. These nanoviricides were also found to be highly effective against common influenza (H1N1) in animal models.

The Company has previously reported positive results for its Ebola program. The first part of the program consisted of cell culture studies of the effect of nanoviricides against Ebola virus. Several nanoviricide drug candidates showed very high efficacy against Ebola in these studies. These studies were conducted by scientists at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID). Subsequently, the Company was invited to submit a grant application to the TMTI program of the Department of Defense (DoD) and did so this January. The objective of the grant application is to further develop both the Ebola and Dengue programs of the Company. The DoD is interested in further development of our broad-spectrum nanoviricides in order to minimize stockpiling costs while still achieving high efficacies against a broad range of viruses.

The Company previously reported that it has signed certain agreements regarding further development of its eye drug candidate. In addition, several other potential collaboration partners have expressed a strong interest in pursuing co-development opportunities for the Company’s other drug candidates. The Company is actively pursuing these opportunities.

“We have attained strong positive achievements in the past twelve months in all of our drug development programs,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “We are confident that we will achieve further successes in our drug development and commercialization programs during the next calendar year as well.”

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.



Realpennies.com



Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on http://www.realpennies.com/start.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

RealPennies.com

Phone: 212-662-2147

info [at] realpennies.com